Top 5 Stock Winners for Monday: Aspen, SoFi, Flexion Therapeutics
Shares ended lower on Monday as investors braced for a key week on Wall Street that could set the direction of the market in the final months of the year.
Here are some of the biggest market winners for Monday:
1. Aspen Technology | 12% increase
Aspen technology (AZPN) – Get the report from Aspen Technology, Inc. shares surged after Emerson Electric (DME) – Get the Emerson Electric Co. announced plans for an $ 11 billion merger with the asset optimization software company that they believe will accelerate their combined growth in the industrial software sector. Aspen shareholders will receive $ 87 in cash, along with 0.42 shares of the combined company.
2. Sofi Technologies | 13% increase
Sofi Technologies actions (SOFI) – Get the SOFI TECHNOLOGIES INC report climbed after Morgan Stanley analyst Betsy Graseck launched the financial services firm’s coverage online with an overweight rating and a price target of $ 25. She called SoFi a “powerful story of revenue growth” as it increases its share of the consumer financial services portfolio.
3. Flexion therapy | 58% increase
Flexion therapy (FLXN) – Get the report Flexion Therapeutics, Inc. Shares soared after Tampa, Fla.-based Pacira BioSciences said it is acquiring the biopharmaceutical company for $ 8 a share in cash, plus a non-tradable conditional value of up to $ 8.50 per share in cash, as part of a deal to expand its position in non-opioid pain management.
4. Adamas Pharmaceuticals | 75% increase
Adamas Pharmaceuticals shares (ADMS) – Get the report from Adamas Pharmaceuticals, Inc. soared after Supernus Pharmaceuticals announced the acquisition of the drugmaker for around $ 400 million. Adamas Pharma shareholders will receive an upfront cash payment of $ 8.10 per share. The deal is expected to be finalized in Q4 or Q1 2022.
5. Ocular therapy | 15% increase
Ocular therapy (OCUL) – Get the Ocular Therapeutix Inc report Shares surged after a post on the U.S. Food and Drug Administration’s website indicated approval of the company’s new application for the company’s supplemental drug, Dextenza, as a treatment for itchy eyes related to allergic conjunctivitis. Dextenza has previously been approved as a treatment for eye inflammation and pain after eye surgery.